Fortrea Sees Obesity Drug Development Shifting Toward Long-Term Outcomes in 2027
Fortrea expects obesity drug development to increasingly focus on long-term health outcomes in 2027.
Related stories
Spartan Delta Reports Q3 Results, Raises 2026 Capital Plan and Sets 2027 Guidance
Third-quarter Adjusted Funds Flow was $109.5 million, up 117% year over year, on production of 53,448 BOE/d and record 46% liquids weighting. Spartan raised its 2026 capital progra
M impact | EQUITY | Nov 04, 2026, 02:02 PM UTC
Dolphin to Host Q3 2026 Earnings Call on November 10
Dolphin said it will host its third-quarter 2026 earnings conference call on November 10, 2026.
M impact | EQUITY | Nov 04, 2026, 02:01 PM UTC
Immunome Reports 53% ORR in 19 B-NHL Patients
At the June 26, 2026 interim cutoff, 10 of 19 response-evaluable B-NHL patients had an overall response, including five complete and five partial responses. In the 11-patient DLBCL
M impact | EQUITY | Nov 04, 2026, 02:01 PM UTC
SM Energy Reports Third-Quarter Revenue of $2.17 Billion
Third-quarter net income was $93 million and diluted EPS was $0.39, compared with $155 million and $1.35 a year earlier. Production averaged 433.1 MBOE per day, down 2% sequentiall
M impact | EQUITY | Nov 04, 2026, 02:01 PM UTC
Nomad Foods Q3 Adjusted Earnings Fall as Revenue Rises
Nomad Foods maintained its 2026 adjusted earnings guidance.
M impact | EQUITY | Nov 04, 2026, 02:01 PM UTC
Scotiabank to announce fourth-quarter 2026 results
Scotiabank says it will announce its fourth-quarter results on Wednesday, Dec. The announcement date is incomplete in the source.
M impact | EQUITY | Nov 04, 2026, 02:00 PM UTC